Herein we report uncovering of a new function of personal glucose meter (PGM), namely, dosedependent response of nicotinamide coenzymes (NADH), and developing a one-step homogeneous assay of targets that are difficult to be recognized by DNAzymes, aptamers or antibodies, and without the need for conjugation and multiple steps of sample dilution, separation, or fluid manipulation. The method is based on the target-induced consumption or production of NADH through cascade enzymatic reactions. Since a large number of commercially available enzymatic assay kits in the clinical labs utilize NADH in their detection, this discovery that links the readout function of PGM with NADH will allow transforming almost all of these clinical lab tests into POC tests using PGM.
Graphical AbstractA newly discovered function of glucose meter, namely, dose-dependent response of nicotinamide coenzymes (NADH), can serve as the signal readout for highly sensitive blood analysis in a single step.Correspondence to: Yi Lu, yi-lu@illinois.edu.
HHS Public AccessAuthor manuscript Angew Chem Int Ed Engl. Author manuscript; available in PMC 2017 January 11. Point-of-care (POC) devices that allow rapid, on-site, and affordable detection and monitoring of health biomarkers at home or away from clinical labs have received increasing attention in modern medicine. [1] Despite the importance, few POC devices are commercially available, partly due to high costs of research and development, and for those devices that are developed, they are often dedicated devices that can detect a single or limited targets. To overcome these limitations, we and others have taken advantage of existing POC devices, such as personal glucose meters (PGMs), and adapt them to measure a wide range of targets. [2] In doing so, we can bypass the costly development process and allow using a single device to measure many targets. [3] A key challenge in this endeavor is to find a way to translate recognition of many targets into an easily measurable signal using a PGM. To meet the challenge, we and others have demonstrated coupling of target binding by DNAzymes, aptamers, DNA and antibodies with enzymes such as invertase or glucoamylase, which can convert sugars that do not register any reading on PGM (e.g., sucrose and amylose) into glucose detectable by PGM.Despite substantial progress made in the last few years with using the PGM to quantify nonglucose targets, there are still several issues that need to be addressed before its practical applications in clinical diagnostics is realized. First, the majority of these systems are limited to those targets that can be recognized by DNAzymes, aptamers, DNA or antibodies. Some progress has been made towards the use of PGMs for enzyme activity applications; [4] however, it either requires sophisticated syntheses of the enzyme substrates that covalently link to glucose or is not transferable to many targets as a general strategy. Second, they require conjugation of the recognition elements (e.g., apatamers or antibodies) ...